7 completed. 7 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 4 | Completed 4 |
Follow Relapse: new trials by email Literature Review of Relapse trials Research Report on Relapse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML LP-108, LP-108 and azacitidine - AML/MDS, CMML | Phase 1 | Completed | Newave Pharmaceutical Inc | 32 | 2020-07-06 | 2026-01-23 |
| CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma CD19 CAR T cells - Lymphomas Non-Hodgkin's B-Cell, Relapse | Phase 1 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2017-06-08 | 2026-02-11 |
| Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies Carfilzomib, Tacrolimus - Hematologic Malignancies, Relapse | Phase 1 / Phase 2 | Completed | University of Michigan Rogel Cancer Center | 53 | 2014-10-01 | 2022-01-03 |
| TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma TPI 287 - Neuroblastoma, Medulloblastoma | Phase 1 | Completed | Giselle Sholler | 18 | 2009-03-01 | 2024-08-06 |
| Amplifying Graft-Versus-Tumor Effect by Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion donor lymphocyte infusion - Hematologic Neoplasms, Relapse | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 21 | 2005-12-01 | 2011-01-24 |
| Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma Revlimid - Relapse, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Completed | University of Wuerzburg | 53 | 2004-09-01 | 2009-08-04 |
| A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients bortezomib - Refractory, Multiple Myeloma | Phase 1 / Phase 2 | Completed | Janssen Pharmaceutical K.K. | 35 | 2004-05-01 | 2011-05-17 |
Recurrence (7) · Multiple Myeloma (3) · Hematologic Neoplasms (2) · Lymphoma (2) · Graft vs Host Disease (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, B-Cell (1) · Medulloblastoma (1) · Neuroblastoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Disease Attributes (7) · Neoplasms (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Hemic and Lymphatic Diseases (6) · Neoplasms by Histologic Type (6) · Hematologic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphoproliferative Disorders (5) · Blood Protein Disorders (3) · Cardiovascular Diseases (3) · Hemorrhagic Disorders (3) · Hemostatic Disorders (3) · Lymphatic Diseases (3)
Azacitidine (1) · Bortezomib (1) · Lenalidomide (1) · TPI-287 (1) · Tacrolimus (1) · carfilzomib (1)
Assistance Publique - Hôpitaux de Paris (1) · Giselle Sholler (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Janssen Pharmaceutical K.K. (1) · Newave Pharmaceutical Inc (1) · University of Michigan Rogel Cancer Center (1) · University of Wuerzburg (1)
United States (3) · China (1) · France (1) · Germany (1) · Spain (1)
Attaphol Pawarode, M.D. (1) · Dehui Zou, Dr. (1) · Giselle Sholler, MD (1) · Ralf Bargou, MD (1)